Published in J Clin Microbiol on June 01, 1988
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. J Clin Microbiol (1992) 1.50
Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clin Microbiol Rev (2015) 1.48
Carcinoma of the gallbladder--is it a sequel of typhoid? Dig Dis Sci (2000) 1.14
Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun (2000) 0.99
Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast. Eur J Epidemiol (2005) 0.97
Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob Agents Chemother (1993) 0.93
Risk factors for typhoid fever among adult patients in Diyarbakir, Turkey. Epidemiol Infect (2005) 0.90
A typhoid fever outbreak in a slum of South Dumdum municipality, West Bengal, India, 2007: evidence for foodborne and waterborne transmission. BMC Public Health (2009) 0.89
Epidemiology of typhoid fever in Singapore. Epidemiol Infect (1993) 0.86
Chronic typhoid infection and the risk of biliary tract cancer and stones in Shanghai, China. Infect Agent Cancer (2011) 0.78
The 'farm to plate' approach to food safety - Everyone's business. Can J Infect Dis (2002) 0.75
Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc Soc Exp Biol Med (1953) 5.33
Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med (1987) 2.83
Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi. J Clin Microbiol (1980) 1.90
Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet (1983) 1.78
A CHALLENGE TO THE VALIDITY OF THE VI TEST FOR THE DETECTION OF CHRONIC TYPHOID CARRIERS. Am J Public Health Nations Health (1964) 1.70
Surface polysaccharide from Staphylococcus aureus M that contains taurine, D-aminogalacturonic acid, and D-fucosamine. J Bacteriol (1974) 1.64
Bacteriophage types of Salmonella typhi in the United States from 1974 through 1981. J Clin Microbiol (1983) 1.41
Vi serology in the detection of typhoid carriers. Lancet (1981) 1.39
Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 1.35
Typhoid fever in San Antonio, Texas: an outbreak traced to a continuing source. J Infect Dis (1984) 1.10
Typhoid fever in the United States, 1975 and 1976. J Infect Dis (1979) 1.06
Identification of a carrier by using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever on an Indian reservation. J Clin Microbiol (1983) 1.05
Typhoid in the United States and the risk to the international traveler. J Infect Dis (1983) 1.01
Identification of Salmonella typhi in faecal specimens by an antiserum-agar method. J Med Microbiol (1980) 0.97
A widespread epidemic of typhoid fever traced to a common exposure. N Engl J Med (1958) 0.93
Epidemiology of Salmonella typhi infection in a migrant labor camp in Dade County, Floida. J Infect Dis (1974) 0.91
Vi serology in screening of typhoid carriers: improved specificity by detection of Vi antibodies by counterimmunoelectrophoresis. J Hyg (Lond) (1982) 0.90
A typhoid fever outbreak on a university campus. Arch Intern Med (1969) 0.81
Counterimmunoelectrophoresis in the serological diagnosis of typhoid fever. J Diarrhoeal Dis Res (1983) 0.80
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med (1996) 4.03
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med (1988) 3.74
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Environmental risk factors for Lyme disease identified with geographic information systems. Am J Public Health (1995) 2.78
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med (1999) 2.53
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia (2011) 2.43
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet (1999) 2.37
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature (2000) 2.24
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med (1994) 2.23
Production of monovalent antisera by induction of immunological tolerance for capsular typing of Streptococcus pneumoniae. FEMS Microbiol Lett (1992) 2.19
A 3-year-old boy's chronic diarrhea and unexplained death. J Am Acad Child Adolesc Psychiatry (1991) 2.19
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford) (2008) 1.80
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Use of antiserum agar plates for serogrouping of meningococci. J Clin Pathol (1977) 1.74
Investigation of an outbreak of Salmonella enteritidis gastroenteritis associated with consumption of eggs in a restaurant chain in Maryland. Am J Epidemiol (1988) 1.71
Predicting worsening asthma control following the common cold. Eur Respir J (2008) 1.70
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun (1993) 1.70
A multistate outbreak of oyster-associated gastroenteritis: implications for interstate tracing of contaminated shellfish. J Infect Dis (1995) 1.69
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
Effect of bran particle size on stool weight. Gut (1978) 1.63
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest (1997) 1.63
Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect Immun (1979) 1.61
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 1.59
Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med (2001) 1.58
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest (2001) 1.57
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
A geographic information systems application for disease surveillance. Am J Public Health (1998) 1.55
Tracheobronchopathia osteochondroplastica presenting as right middle lobe collapse. Diagnosis by bronchoscopy and computerized tomography. Chest (1988) 1.53
Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis (2006) 1.52
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ (1978) 1.52
Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine (1998) 1.51
Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of haemophilus influenzae type B. J Immunol (1974) 1.49
Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun (1976) 1.49
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate. J Pediatr (1989) 1.46
Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun (1992) 1.45
Persistence of cholera in the United States: isolation of Vibrio cholerae O1 from a patient with diarrhea in Maryland. J Clin Microbiol (1986) 1.44
Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun (1991) 1.44
An outbreak of Hemophilus influenzae type b meningitis in an enclosed hospital population. J Pediatr (1976) 1.44
The infant rat as a model of bacterial meningitis. J Infect Dis (1977) 1.44
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Age-related susceptibility to Haemophilus influenzae type b disease in rabbits. Infect Immun (1971) 1.43
Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun (1989) 1.42
Quantitative studies of the immunoglobulin sequence in the response of the rabbit to a somatic antigen. J Exp Med (1966) 1.40
Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun (1991) 1.39
Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med (1998) 1.39
Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis (1999) 1.39
Diagnostic yield of bronchoalveolar lavage and bronchoscopic lung biopsy for detection of Pneumocystis carinii. Mayo Clin Proc (1996) 1.38
Structural studies on the sialic acid polysaccharide antigen of Escherichia coli strain Bos-12. Biochemistry (1977) 1.38
Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect Immun (1989) 1.37
Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun (1999) 1.36
Immunity to Hemophilus influenzae type b. I. The isolation, and some physicochemical, serologic and biologic properties of the capsular polysaccharide of Hemophilus influenzae type b. J Immunol (1971) 1.36
Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 1.35